Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNK | O75909 | 18/20 | 0.72 |
| ▸ | CDK12 | Q9NYV4 | 18/20 | 0.72 |
| ▸ | CCNE1 | P24864 | 12/20 | 0.59 |
| ▸ | CDK2 | P24941 | 12/20 | 0.59 |
| ▸ | CCNT1 | O60563 | 11/20 | 0.59 |
| ▸ | CDK9 | P50750 | 11/20 | 0.59 |
| ▸ | CDK7 | P50613 | 8/20 | 0.59 |
| ▸ | CCNH | P51946 | 8/20 | 0.59 |
| ▸ | MNAT1 | P51948 | 8/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30204002 | 0.91 | CCNK (0.67) | CCNKCDK12CCNE1CDK2CCNT1 | |
| SCHEMBL25602582 | 0.91 | CCNK (0.67) | CCNKCDK12CCNE1CDK2CCNT1 | |
| SCHEMBL26967518 | 0.87 | CCNK (0.61) | CCNKCDK12CCNE1CDK2CCNT1 | |
| SCHEMBL26967469 | 0.86 | CCNK (0.74) | CCNKCDK12CCNE1CDK2CCNT1 | |
| SCHEMBL25225790 | 0.85 | CCNK (0.67) | CCNKCDK12CCNE1CDK2CCNT1 | |
| SCHEMBL25267992 | 0.85 | CCNK (0.78) | CCNKCDK12CCNE1CDK2CCNT1 | |
| SCHEMBL26967509 | 0.85 | CCNK (0.53) | CCNKCDK12CCNE1CDK2CCNT1 | |
| SCHEMBL25224398 | 0.84 | CCNK (0.73) | CCNKCDK12CCNE1CDK2CCNT1 | |
| SCHEMBL21179130 | 0.84 | CCNK (0.57) | CCNKCDK12CCNE1CDK2CCNT1 | |
| SCHEMBL24839671 | 0.84 | CCNK (1.00) | CCNKCDK12CCNE1CDK2CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4295852-A2 | PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |